ten23 health Launches New GMP-Certified QC Services at Basel and Visp

• ten23 health has launched new GMP-certified quality control (QC) services at its Basel and Visp facilities.

• The new services complement ten23 health’s development and manufacturing capabilities for sterile pharmaceutical products.

ten23 health has announced the launch of its quality control (QC) and testing services at its Basel (BASE) and Visp (VIVA2) facilities, following the receipt of GMP establishment licences from Swissmedic. The services were officially inaugurated with an event attended by local economic leaders and company executives.

The new QC laboratories, operational since 2024, now provide analytical method validation, method transfer, QC release testing, and QC stability testing at the Basel facility, alongside microbiological and in-process control testing at the Visp site. The QC offering supports sterile pharmaceutical products, including biologics, peptides, small molecules, bioconjugates, and oligonucleotides.

The services are available either as stand-alone offerings or combined with ten23 health’s development and GMP manufacturing services for sterile products, supporting customers with a fully integrated approach across both Swiss locations.

“Having obtained the GMP licences for our QC services laboratories in both Basel and Visp represents a pivotal moment for ten23 health and underscores our dedication to Swiss excellence in providing integrated services for pharmaceutical development, manufacturing and testing,” commented Dr. Susanne Jörg, Chief Customer Delivery Officer (COO) at ten23 health.